Man Group PLC Editas Medicine, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Man Group PLC holds 52,733 shares of EDIT stock, worth $69,080. This represents 0.0% of its overall portfolio holdings.

Number of Shares

52,733

Previous 55,022 4.16%

Holding current value

$69,080

Previous $256,000 30.08%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $7,759 - $13,642	-2,289 Reduced 4.16%	52,733 $179,000
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $218,299 - $340,303	-46,745 Reduced 45.93%	55,022 $256,000
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $176,670 - $278,200	25,131 Added 32.79%	101,767 $755,000
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $3.51 Million - $6.24 Million	-561,546 Reduced 87.99%	76,636 $776,000
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $705,784 - $949,545	-101,992 Reduced 13.78%	638,182 $4.98 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $1.19 Million - $2.15 Million	187,810 Added 34.0%	740,174 $6.09 Million
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $1.01 Million - $1.65 Million	142,984 Added 34.93%	552,364 $4 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $829,728 - $1.32 Million	99,727 Added 32.21%	409,380 $3.63 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $3.63 Million - $5.8 Million	298,655 Added 2715.54%	309,653 $3.79 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $109,870 - $234,807	10,998 New	10,998 $130,000
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $551,390 - $1.02 Million	-14,041 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $206,607 - $373,993	6,603 Added 88.77%	14,041 $796,000
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $295,362 - $673,734	7,438 New	7,438 $313,000
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $557,912 - $1.74 Million	-20,610 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $980,276 - $1.3 Million	-34,935 Reduced 62.89%	20,610 $578,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $288,563 - $535,635	-15,598 Reduced 21.92%	55,545 $1.64 Million
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $641,967 - $1.41 Million	43,143 Added 154.08%	71,143 $1.41 Million
Q4 2019 Feb 18, 2020	BUY	$19.49 - $32.63 $50,673 - $84,838	2,600 Added 10.24%	28,000 $829,000
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $870,812 - $1.04 Million	-38,720 Reduced 60.39%	25,400 $578,000
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $126,976 - $172,112	-6,200 Reduced 8.82%	64,120 $1.59 Million
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $1.37 Million - $1.86 Million	70,320 New	70,320 $1.72 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $242,739 - $337,025	-8,779 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $3.06 Million - $3.99 Million	-97,294 Reduced 91.72%	8,779 $315,000
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $3.17 Million - $4.68 Million	106,073 New	106,073 $3.52 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account